01—Abstract
Summary
Summary of the 10-K filed March 7, 2003. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (filed under this name; the filing is for fiscal 2002) reports a net loss of $86.1 milliona for the year ended December 31, 2002, compared to $71.2 million in 2001 and $75.3 million in 2000, with an accumulated deficit of $287.4 million.
Total revenues rose to $44.3 millionb from $41.0 million in 2001, driven mainly by new collaborations with GlaxoSmithKline, Bristol-Myers Squibb and Protein Design Labs. Research and development expenses increased to $112.0 million from $82.7 million, and the company states it expects operating expenses to increase significantly and negative operating cash flow to continue. Cash, cash equivalents, short-term investments and restricted cash totaled $222.0 million at year-end, and the company says this is sufficient for its currently planned operations for at least the next two years.
The company's most advanced clinical program is the rebeccamycin analogue (XL 119), in-licensed from Bristol-Myers Squibb, which has completed Phase I testing and is in a Phase II program conducted by the National Cancer Institute. Its lead proprietary compound, XL 784, is in regulatory toxicology studies, with an IND filing expected in 2003. Revenue is concentrated: two collaborators accounted for approximately 39%c and 25% of 2002 total revenue.
The October 2002 GlaxoSmithKline alliance is a significant event for investors. GSK paid a $30.0 milliond upfront fee, $10.0 million in annual research funding, purchased 2,000,000 shares at $7.00 per share, and provided a loan facility of up to $85.0 million, of which $25.0 million was borrowed in December 2002. Stockholders' equity declined to $175.9 million from $237.2 million, and long-term obligations rose to $65.4 million.
02—Key points
Key Highlights
- Net loss of $86.1 million in 2002 (or $1.52 per share), up from $71.2 million in 2001; accumulated deficit of $287.4 million
- Total revenues of $44.3 million in 2002, versus $41.0 million in 2001, mainly from GlaxoSmithKline, Bristol-Myers Squibb and Protein Design Labs collaborations
- Research and development expenses rose to $112.0 million from $82.7 million, and the company expects operating expenses to increase significantly
- Cash, cash equivalents, short-term investments and restricted cash of $222.0 million at December 31, 2002, said to fund planned operations for at least two years
- Rebeccamycin analogue (XL 119) has completed Phase I testing and is in NCI-conducted Phase II trials; XL 784 IND filing expected in 2003
- GlaxoSmithKline alliance (October 2002) includes a $30.0 million upfront fee, a $10.0 million annual research funding commitment, and a loan facility of up to $85.0 million
- Revenue concentration: two collaborators represented approximately 39% and 25% of 2002 total revenue
03—Questions
Frequently Asked Questions
How much cash does Exelixis have, and how long will it last?
At December 31, 2002, Exelixis had approximately $222.0 million in cash, cash equivalents, short-term investments and restricted cash. The company believes this, together with funding to be received from collaborators, will be sufficient for at least the next two years, though changes to its operating plan could require it to use resources sooner and it may seek additional financing.
Why did the net loss increase in 2002?
Research and development expenses rose to $112.0 million from $82.7 million, mainly due to increased personnel costs, lab supplies, and licenses and consulting. Total revenues increased only modestly to $44.3 million, so the net loss widened to $86.1 million from $71.2 million.
What is the status of the company's clinical programs?
The rebeccamycin analogue (XL 119) has completed Phase I testing, and its Phase II program is being conducted by the National Cancer Institute. The company will anticipate next development steps following discussions with the FDA. Its lead proprietary compound, XL 784, is undergoing regulatory toxicology studies, and the company expects to file an IND in 2003 if the safety profile remains acceptable.
What are the key terms of the GlaxoSmithKline alliance?
Signed in October 2002, the alliance covers vascular biology, inflammatory disease and cancer. GSK paid a $30.0 million upfront fee and $10.0 million in annual research funding, agreed to pay at least an additional $80.0 million over the first six years, and bought 2,000,000 shares at $7.00 per share for about $14.0 million. A loan facility of up to $85.0 million was provided, with $25.0 million borrowed in December 2002.
What risks are highlighted for investors?
The filing highlights a history of net losses with expected continued losses and negative operating cash flow, dependence on collaborations for nearly all revenue, possible need for additional capital that may be dilutive, lengthy and uncertain FDA regulatory processes, reliance on third-party manufacturers, and a highly volatile stock price. Several collaborations, including the Protein Design Labs funding, are scheduled to expire in 2003 or 2004.
04—Continue